Chief Financial Officer
Education: MSc in Business Economics and Auditing, Executive Management Program, INSEAD.
Background: Johnny Stilou has held numerous Executive positions as Chief Financial Officer within the biotech and pharmaceutical industry, most recently as CFO at Amgen Research Copenhagen and Nuevolution AB (acquired by Amgen). Prior to Nuevolution, he served as CFO at Veloxis Pharmaceuticals until the company was acquired by Asahi Kasei.
Other ongoing assignments: None
Year of commencement of the position: 2021
Scandion Oncology shares and warrants
137,773 shares, 93,330 TO2 warrants, 31,110 TO3 warrants and 482,033 Incentive warrants.